MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has begun dosing patients in the phase 2 trial for Gabapentin GR™ for the treatment of menopausal hot flashes. “We are very excited to have dosed the first patient. Following up on the clinical trial kick-off meeting we held in April, we screened approximately 40 patients last week and dosed four patients yesterday,” said Carl Pelzel, executive vice president and chief operating officer of Depomed. “Even though there have been several previous trials conducted by other investigators, these trials varied considerably in design, including the doses evaluated. We designed our Phase 2 trial as a PK/PD trial to study the dose response of hot flash patients to our proprietary AcuForm™ formulation of Gabapentin. Since our formulation has the potential to provide improved bioavailability and fewer side-effects compared to the immediate release formulation of Gabapentin, this trial will generate dosing and efficacy data that is unique to our patented formulation.”
